1910 - Comparative Efficacy of Zanubrutinib (ZANU) versus Fixed-Duration Acalabrutinib Plus Venetoclax (AV) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL): A Matching-Adjusted Indirect Comparison (MAIC)

Primary Author / Presenter(s)

Talha Munir, MBBS, MRCP, FRCPath, PhD

Consultant Haematologist
Leeds Teaching Hospitals NHS Trust
Leeds, England, United Kingdom

KY

Keri Yang, PhD

BeOne Medicines Ltd., USA
San Carlos, California, United States
SX

Sheng Xu, PhD

BeOne Medicines Ltd
Shanghai, Shanghai, China (People's Republic)
RW

Rhys Williams, PhD

BeOne Medicines Ltd
San Carlos, California, United States
Mazyar Shadman, MD, MPH

Professor
Fred Hutchinson Cancer Center
Seattle, Washington, United States